ArticleBritish journal of cancer2026
Alterations in NK cell subsets and the regulatory role of JAB1 in nasopharyngeal carcinoma with implications for tumor immunity and biomarker development.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigates changes in NK cell subsets in the blood of NPC patients and explores JAB1's role in shaping the tumor immune environment.
methodsWe performed RNA sequencing analyses on NPC PBMCs and tissue samples to identify genes associated with JAB1. Dimensionality reduction and clustering analyses were conducted on paired single-cell RNA sequencing data to explore differences in NK cell subsets. Functional assays assessed the roles of these subsets in various immune environments. Flow cytometry characterised NK cell subsets and cytokine profiles. A humanised immune system mouse model with NPC xenografts supported our findings.
resultsHigher levels of CD16 + CD57 + NK cells in blood correlated with better patient outcomes, while increased CD16- NK cells indicated worse prognoses. JAB1 enhanced NK cell cytotoxicity, indicating its role in immune regulation. NK subsets showed distinct distributions: CD16hiCD57- and CD16hiCD57+ cells were mainly in blood, while CD16loCD57- cells accumulated in tumors. Functional tests revealed some subsets promoted tumor growth while others suppressed it. Expression of JAB1 and CD107a in NK cells demonstrated superior diagnostic and prognostic value compared to traditional tumor markers like SCC and CEA.
conclusionThis study identifies key roles of NK cell subsets and JAB1 in NPC immunity, offering insights for biomarker and immunotherapy target development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.